Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study

There are limited data on the phenotypic and dopamine transporter (DAT) imaging characterization of the Parkinson's disease (PD) patients with leucine rich kinase 2 (LRRK2) and glucosylceramidase beta (GBA) mutations.

[1]  Yen F. Tai,et al.  Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study , 2020, The Lancet Neurology.

[2]  Y. Benjamini,et al.  Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease , 2019, Front. Neurol..

[3]  Z. Gan-Or,et al.  Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations. , 2019, Parkinsonism & related disorders.

[4]  T. Simuni,et al.  New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics. , 2019, Parkinsonism & related disorders.

[5]  A. Xie,et al.  Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease. , 2018, Parkinsonism & related disorders.

[6]  Norbert Schuff,et al.  The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort , 2018, Annals of clinical and translational neurology.

[7]  Günther Deuschl,et al.  Movement disorder society criteria for clinically established early Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[8]  Z. Gan-Or,et al.  GBA-Associated Parkinson’s Disease and Other Synucleinopathies , 2018, Current Neurology and Neuroscience Reports.

[9]  Shu G. Chen,et al.  Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls , 2018, Journal of the Neurological Sciences.

[10]  K. Marder,et al.  Progression in the LRRK2-Asssociated Parkinson Disease Population , 2018, JAMA neurology.

[11]  R. Barker,et al.  Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[12]  D. Berg,et al.  Cognitive impairment in Glucocerebrosidase (GBA)‐associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles , 2017, Movement disorders : official journal of the Movement Disorder Society.

[13]  V. Sossi,et al.  Serotonin transporter binding and motor onset of Parkinson's disease in asymptomatic LRRK2 mutation carriers: a cross-sectional study , 2017, The Lancet Neurology.

[14]  L. Pihlstrøm,et al.  Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature , 2017, European journal of neurology.

[15]  A. Mirelman,et al.  High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews. , 2016, JAMA neurology.

[16]  K. Marder,et al.  Neuropsychiatric characteristics of GBA-associated Parkinson disease , 2016, Journal of the Neurological Sciences.

[17]  M. T. Pellecchia,et al.  Impulsive-compulsive behaviors in parkin-associated Parkinson disease , 2016, Neurology.

[18]  C. Mariani,et al.  Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters , 2016, Annals of neurology.

[19]  R. Barker,et al.  Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's , 2016, Annals of neurology.

[20]  M. Albert,et al.  GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[21]  A. Desautels,et al.  GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder , 2015, Annals of clinical and translational neurology.

[22]  G. Rouleau,et al.  LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis. , 2015, Parkinsonism & related disorders.

[23]  T. Foroud,et al.  Novel recruitment strategy to enrich for LRRK2 mutation carriers , 2015, Molecular genetics & genomic medicine.

[24]  J. Zarranz,et al.  Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene. , 2015, Parkinsonism & related disorders.

[25]  T. Montine,et al.  Cognitive profile of LRRK2‐related Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[26]  D. Berg,et al.  GBA‐associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[27]  A. Schapira,et al.  Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. , 2015, JAMA neurology.

[28]  K. Marder,et al.  Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. , 2014, Parkinsonism & related disorders.

[29]  E. Ginns,et al.  Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. , 2014, Molecular genetics and metabolism.

[30]  P. Mazzoni,et al.  Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.

[31]  J. Trojanowski,et al.  Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. , 2013, JAMA neurology.

[32]  J. Duda,et al.  Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease. , 2012, Parkinsonism & related disorders.

[33]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[34]  D. Berg,et al.  GBA-associated PD presents with nonmotor characteristics , 2011, Neurology.

[35]  A. Brice,et al.  LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort. , 2010, Parkinsonism & related disorders.

[36]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[37]  K. Marder,et al.  Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. , 2010, Archives of neurology.

[38]  A. Mirelman,et al.  LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease , 2010, neurogenetics.

[39]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[40]  C. Mariani,et al.  LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. , 2006, Parkinsonism & related disorders.

[41]  A. Antonini,et al.  Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation , 2006, Movement disorders : official journal of the Movement Disorder Society.

[42]  Vesna Sossi,et al.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.

[43]  M. Farrer,et al.  Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. , 2005, Parkinsonism & related disorders.

[44]  V. Bonifati.  Genetics of Parkinson's disease--state of the art, 2013. , 2014, Parkinsonism & related disorders.